Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin

BMC Research Notes

Wolfgang Opferkuch³  Johannes Huebner¹  Manfred Kist²  Nicole Wüppenhorst²  Barbara Baars³  Türkan Sakinc³ 

[1] Division of Infectious Diseases, University Hospital Freiburg, Hugstetter Strasse 55, Freiburg, D-79106, Germany;Institute of Medical Microbiology and Hygiene, National Reference Centre for Helicobacter, University Medical Centre Freiburg, Freiburg, Germany;Department of Medical Microbiology, Ruhr-University Bochum, Universitätstraße 150, Bochum, 44801, Germany

关键词: 23S rRNA;    Synergistic effect;    Helicobacter pylori;   

Others  :  1165337
DOI  :  10.1186/1756-0500-5-603

 received in 2012-07-18, accepted in 2012-10-19,  发布年份 2012

【 摘 要 】

Background

Clarithromycin (CLR) is the most commonly recommended antibiotic in Helicobacter pylori eradication regimens, but the prevalence of CLR-resistant H. pylori is increasing. CLR resistance is associated with mutations in the 23S rRNA gene. However, H. pylori eradication can still be achieved with triple therapy, and an additive effect may occur with multiple antibiotics.

Methods

Twenty-six CLR-resistant strains were examined. The MIC of clarithromycin was determined by agar-dilution-testing on Columbia agar, as described elsewhere. The conserved region of the H. pylori 23S rRNA gene between nucleotide positions 1445 and 2846 [GenBank: U27270] was amplified. RFLP and sequence analysis were performed with the 1402-bp PCR product. Synergy between clarithromycin and amoxicillin was assessed using the agar dilution checkerboard technique. To confirm the correlation between mutation and synergistic effect with subinhibitory concentrations of AMX, site-directed mutagenesis was performed in four CLR-susceptible H. pylori isolates.

Results

Twenty-six clarithromycin-resistant strains were examined. The conserved region of the H. pylori 23S rRNA gene was amplified, and the purified PCR product was checked for mutations by restriction fragment length polymorphism (RFLP) analysis and sequencing. A synergistic effect was found in only three of the 12 H. pylori strains (25%) with the A2142G mutation and five of the 10 H. pylori strains (50%) with the A2143G mutation (fractional inhibitory concentration: FIC < 0.5, minimal inhibitory concentration: MIC<2 mg/L) was found. Site-directed mutagenesis was performed in four CLR-susceptible H. pylori isolates.

Three of these isolates harboring a mutation in position A2143G grew under selection with CLR (MIC >16 mg/L), and all three strains showed the synergistic effect (FIC<0.5). In contrast, three of the same four strains transformed with DNA fragments with a mutation in position A2142G were resistant to CLR (MIC>16 mg/L) and showed no synergism with amoxicillin (FIC>2).

Conclusions

Here we demonstrate that in 100% of the in vitro transformed strains, a mutation at position A2143G leads to a synergistic effect between clarithromycin and amoxicillin, whereas a mutation at position at A2142G had no discernible effect.

【 授权许可】

   
2012 Sakinc et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Blaser MJ: Ecology of Helicobacter pylori in the human stomach. J Clin Investig 1997, 100:759-762.
• [2]De Francesco V, Zullo A, Lerardi E, et al.: Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010, 65:327-332.
• [3]Vallejos C, Garrido L, Caceres D, et al.: Prevalencia de la Resistencia a metronidazol, claritromicina y tetraciclina en Helicobacter pylori: studio de base hospitalaria. Rev Med Chile 2007, 135:287-293.
• [4]Taylor DE, Ge Z, Purych D: Cloning and sequence analysis of the two copies of 23S rRNA genes from Helicobacter pylori and association of clarithromycin resistance with 23 rRNA mutations. Antimicrob Agents Chemother 1997, 41:2621-2628.
• [5]Ge W, Taylor DE: Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 1998, 42:1952-1958.
• [6]Wurzer HL, Rodrigo D, Stamler D, et al.: b. Pharmacol Ther 1998, 11:943-952.
• [7]Baars B, Sakinc T, Opferkuch W: Die In-vitro-Wirksamkeit von Antibiotika-Kombinationen auf Helicobacter pylori. Chemotherapie Journal 2008, 17:100-106.
• [8]Eliopoulos GM, Moellering RC: Antimicrobial combinations. In Antibiotics in laboratory medicine. 4th edition. Edited by Lorian V. Baltimore Md: The Williams& Williams Co; 1996:330-396.
• [9]Agudo S, Pérez-Pérez G, Alarcón T, et al.: Rapid detection of clarithromycin resistant Helicobacter pylori strains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. Rev Esp Quimioter 2011, 24:32-36.
• [10]Rimbara E, Noguchi N, Sasatsu M: Novel mutation in 23S rRNA that confers low-lewel resistance to clarithromycin in Helicobacter pylori. Antimicrob Agents Chemother 2008, 52:3465-3466.
• [11]Hirata K, Suzuki H, Nishizawa T, et al.: Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori. J Gastroenterol Hepatol 2010, 1:75-79.